We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
59 hedge funds and large institutions have $11.3M invested in Galectin Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
74% more call options, than puts
Call options by funds: $327K | Put options by funds: $188K
22% more capital invested
Capital invested by funds: $9.26M → $11.3M (+$2.06M)
0.2% less ownership
Funds ownership: 11.89% → 11.69% (-0.2%)
2% less funds holding
Funds holding: 60 → 59 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
Holders
59
Holders Change
-1
Holders Change %
-1.67%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
14
Closed
8
Calls
$327K
Puts
$188K
Net Calls
+$139K
Net Calls Change
+$127K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.9K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$33K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$25K |
| 4 |
VF
Virtu Financial
New York
|
+$24K |
| 5 |
Mariner
Overland Park,
Kansas
|
+$21.2K |
Top Sellers
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$61.4K |
| 2 |
Morgan Stanley
New York
|
-$39.8K |
| 3 |
Renaissance Technologies
New York
|
-$36K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$32.6K |
| 5 |
Millennium Management
New York
|
-$31K |
